Merck-European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

默克(US:MRK) Businesswire·2025-11-19 19:30

监管批准 - 欧洲委员会批准了默沙东抗PD-1疗法KEYTRUDA®（帕博利珠单抗）新的皮下注射给药途径和新的剂型（注射用溶液）[1] - 该药物在欧盟将以KEYTRUDA SC™的名称上市[1] 产品信息 - 此次获批的KEYTRUDA SC™在美国的名称为KEYTRUDA QLEXTM（帕博利珠单抗和透明质烷醇酶α-pmph）[1]